Do inhaled anticholinergics increase the risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease?

Ähnliche Einträge

• A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD
  von: Daniel E Hilleman, et al.
  Veröffentlicht: (2009-06-01)
• Inhaled anticholinergic use and all-cause mortality among elderly Medicare beneficiaries with chronic obstructive pulmonary disease
  von: Ajmera M, et al.
  Veröffentlicht: (2013-06-01)
• Safety and tolerability of inhalational anticholinergics in COPD
  von: Sharafkhaneh A, et al.
  Veröffentlicht: (2013-03-01)
• Cardiovascular Events According to Inhaler Therapy and Comorbidities in Chronic Obstructive Pulmonary Disease
  von: Kim EK, et al.
  Veröffentlicht: (2024-01-01)
• Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study
  von: Yen-Fu Chen, et al.
  Veröffentlicht: (2019-12-01)